| Literature DB >> 16271436 |
Rosemary M Cesario1, Jessica Stone, Wan-Ching Yen, Reid P Bissonnette, William W Lamph.
Abstract
This study evaluated the anti-tumor efficacy of combining the RXR agonist, bexarotene, with the PPARgamma agonist, rosiglitazone, in colon cancer. Moser, a human colon cancer cell line, was treated with bexarotene and rosiglitazone alone or in combination and the effect on growth and differentiation were examined. The data demonstrated that the bexarotene/rosiglitazone combination produced greater efficacy in growth inhibition than either single agent. Furthermore, combination treatment acted cooperatively to decrease COX-2 expression and PGE2 synthesis while increasing expression of the differentiation marker, CEA. These findings were confirmed in vivo in a Moser xenograft tumor model. Collectively, our data suggest a potential role for utilizing a combination regimen of a RXR and PPARgamma agonist in the treatment of colon cancer.Entities:
Mesh：
Substances：
Year: 2005 PMID： 16271436 DOI： 10.1016/j.canlet.2005.09.010
Source DB: PubMed Journal: Cancer Lett ISSN： 0304-3835 Impact factor: 8.679